Memorial Sloan Kettering Cancer Center

Adjuvance Technologies, Inc.

Sloan-Kettering Institute for Cancer Research

Naga Vara Kishore Pillarsetty

Jason S Lewis

Philip O Livingston

Steven M Larson

Derek Shieh Tan

David Y Gin

Jeffrey R Gardner

Eric K Chea

Govind Ragupathi

Lars Nordstroem

J Tyler Martin

Gabriela Chiosis

Tony Taldone

Alberto Fernandez-Tejada

Mary L Alpaugh

Erica M Gomes-Dagama

Sang-gyu Lee

Alberto Fernandez-tejada

Jason Lewis

Eric Chea

David Y (Deceased) Gin

Derek Tan

Jeffrey Gardner

Philip Livingston

The present application relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, and intermediates thereto. The application also provides pharmaceutical compositions comprising compounds of the present invention and methods of using said compounds or compositions in the treatment of and immunization for infectious diseases.

Triterpene saponin analogues

Described herein are liposome-based nanocarriers that selectively target bone marrow, minimize tumor delivery, and maintain high drug concentrations in bone marrow when compared to conventional systemic delivery. The composition of the liposome-based nanocarriers may also be tuned to selectively target lymph nodes and other reticuloendothelial system organs (e.g., spleen, e.g., liver). Also described herein are methods of imaging and mapping the bone marrow and/or other reticuloendothelial system organs using the described liposome-based nanocarriers. These methods provide high resolution non-invasive and quantitative imaging via PET, which offers advantages over conventional imaging/tracking methods. Furthermore, in certain embodiments, the liposome-based carriers are used to stabilize and deliver radioprotectant/free radical scavenger drugs to the bone marrow, thereby protecting the bone marrow from subsequent radiation exposure, thereby limiting the adverse impact of radiation exposure on the individual.

Bone marrow-, reticuloendothelial system-, and/or lymph node-targeted radiolabeled liposomes and methods of their diagnostic and therapeutic use

This invention concerns various methods of using labeled HSP90 inhibitors to improve treatment of cancer patients with HSP90 inhibitors, including ex vivo and in vivo methods for determining whether a tumor will likely respond to therapy with an HSP90 inhibitor.

Uses of labeled HSP90 inhibitors

Growing community of inventors

Jackson Heights, NY, United States of America

Naga Vara Kishore Pillarsetty